Nitric Oxide in the Management of Respiratory Consequences in COVID-19: A Scoping Review of a Different Treatment Approach

Arunibha Ghosh, Betsy Joseph, Sukumaran Anil, Arunibha Ghosh, Betsy Joseph, Sukumaran Anil

Abstract

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) virus causing COVID-19 significantly affects the respiratory functions of infected individuals by massively disrupting the pulmonary oxygenation and activating the synthesis of proinflammatory cytokines, inducing severe oxidative stress, enhanced vascular permeability, and endothelial dysfunction which have rendered researchers and clinicians to depend on prophylactic treatment due to the unavailability of proper disease management approaches. Previous studies have indicated that nitric oxide (NO) application appears to be significant concerning the antiviral activities, antioxidant, and anti-inflammatory properties in relieving disease-related symptoms. To identify, explore, and map the literature on the role of nitric oxide in the management of respiratory consequences in COVID-19 through this scoping review, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed during the search to answer the focal question: "What are the potential uses of nitric oxide in the management of respiratory failure in COVID-19?" Administering exogenous NO in the form of inhaled gas or stimulating the system to produce NO appears to be a suitable option to manage COVID-19-induced pneumonia and respiratory illness. This treatment modality seems to attenuate respiratory distress among patients suffering from severe infections or patients with comorbidities. Exogenous NO at different doses effectively reduces systemic hyperinflammation and oxidative stress, improves arterial oxygenation, and restores pulmonary alveolar cellular integrity to prevent the lungs and other organs from further damage. This therapy could pave the way for better management of COVID-19 before the onset of disease-related complications.

Keywords: acute respiratory distress syndrome [ards]; anti-inflammation; covid -19; cytokine release storm; cytokine storm syndrome; nitric oxide (no); sars-cov-2.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2022, Ghosh et al.

Figures

Figure 1. Mechanism of action depicting antiviral…
Figure 1. Mechanism of action depicting antiviral properties of inhaled nitric oxide
SARS-CoV-2: severe acute respiratory distress syndrome coronavirus 2.
Figure 2. Exogenous nitric oxide and drug-induced…
Figure 2. Exogenous nitric oxide and drug-induced NO production inhibits inflammation, fibrosis, and acute lung injury through cGMP-PDE5 mechanism
cGMP: cyclic guanosine monophosphate, PDE5: phosphodiesterase type 5.

References

    1. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Kirby T. Lancet Respir Med. 2021;9:0–1.
    1. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. Richardson S, Hirsch JS, Narasimhan M, et al. JAMA. 2020;323:2052–2059.
    1. Covid-19: new coronavirus variant is identified in UK. Wise J. BMJ. 2020;371:0.
    1. Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: summarizing the evidences. Lahiri D, Mondal R, Deb S, Bandyopadhyay D, Shome G, Sarkar S, Biswas SC. Diabetes Metab Syndr. 2020;14:1053–1060.
    1. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. Li YC, Bai WZ, Hashikawa T. J Med Virol. 2020;92:552–555.
    1. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. Mao L, Jin H, Wang M, et al. JAMA Neurol. 2020;77:683–690.
    1. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Moriguchi T, Harii N, Goto J, et al. Int J Infect Dis. 2020;94:55–58.
    1. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Rhea EM, Logsdon AF, Hansen KM, et al. Nat Neurosci. 2021;24:368–378.
    1. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. Front Immunol. 2020;11:1991.
    1. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Bestle D, Heindl MR, Limburg H, et al. Life Sci Alliance. 2020;3:0.
    1. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Wang Q, Zhang Y, Wu L, et al. Cell. 2020;181:894–904.
    1. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Am J Respir Crit Care Med. 2020;202:756–759.
    1. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Qi F, Qian S, Zhang S, Zhang Z. Biochem Biophys Res Commun. 2020;526:135–140.
    1. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Zang R, Gomez Castro MF, McCune BT, et al. Sci Immunol. 2020;5:0.
    1. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. Adusumilli NC, Zhang D, Friedman JM, Friedman AJ. Nitric Oxide. 2020;103:4–8.
    1. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Ann Intern Med. 2020;173:268–277.
    1. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Xu Z, Shi L, Wang Y, et al. Lancet Respir Med. 2020;8:420–422.
    1. Severe COVID-19 lung infection in older people and periodontitis. Aquino-Martinez R, Hernández-Vigueras S. J Clin Med. 2021;10:279.
    1. Periodontal disease and senescent cells: new players for an old oral health problem? Aquino-Martinez R, Khosla S, Farr JN, Monroe DG. Int J Mol Sci. 2020;21:7441.
    1. Oral microbiome and SARS-CoV-2: beware of lung co-infection. Bao L, Zhang C, Dong J, Zhao L, Li Y, Sun J. Front Microbiol. 2020;11:1840.
    1. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Wang J, Jiang M, Chen X, Montaner LJ. J Leukoc Biol. 2020;108:17–41.
    1. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. Antiviral Res. 2020;178:104787.
    1. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Chest. 2021;159:85–92.
    1. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Hellwig MD, Maia A. Int J Antimicrob Agents. 2021;57:106248.
    1. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Ahmed S, Karim MM, Ross AG, et al. Int J Infect Dis. 2021;103:214–216.
    1. Remdesivir for the treatment of Covid-19: final report. Beigel JH, Tomashek KM, Dodd LE, et al. N Engl J Med. 2020;383:1813–1826.
    1. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Samudrala PK, Kumar P, Choudhary K, et al. Eur J Pharmacol. 2020;883:173375.
    1. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. Spinner CD, Gottlieb RL, Criner GJ, et al. JAMA. 2020;324:1048–1057.
    1. Tocilizumab in patients hospitalized with Covid-19 pneumonia. Salama C, Han J, Yau L, et al. N Engl J Med. 2021;384:20–30.
    1. Inhaled nitric oxide for the adult respiratory distress syndrome. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. N Engl J Med. 1993;328:399–405.
    1. Ozone therapy for the treatment of COVID-19 pneumonia: a scoping review. Izadi M, Cegolon L, Javanbakht M, et al. Int Immunopharmacol. 2021;92:107307.
    1. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Akerström S, Gunalan V, Keng CT, Tan YJ, Mirazimi A. Virology. 2009;395:1–9.
    1. COVID-19 pathophysiology: interactions of gut microbiome, melatonin, vitamin D, stress, kynurenine and the alpha 7 nicotinic receptor: treatment implications. Anderson G, Reiter RJ. Melatonin Res. 2020;3:322–345.
    1. Potential benefits of tryptophan metabolism to the efficacy of tocilizumab in COVID-19. Belladonna ML, Orabona C. Front Pharmacol. 2020;11:959.
    1. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives. Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. Restor Neurol Neurosci. 2020;38:343–354.
    1. Boosting nitric oxide in stress and respiratory infection: potential relevance for asthma and COVID-19. Ritz T, Salsman ML, Young DA, Lippert AR, Khan DA, Ginty AT. Brain Behav Immun Health. 2021;14:100255.
    1. Sources of vascular nitric oxide and reactive oxygen species and their regulation. Tejero J, Shiva S, Gladwin MT. Physiol Rev. 2019;99:311–379.
    1. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. Akerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist A, Mirazimi A. J Virol. 2005;79:1966–1969.
    1. Nitric oxide (NO) and nanoparticles: potential small tools for the war against COVID-19 and other human coronavirus infections. Pieretti JC, Rubilar O, Weller RB, Tortella GR, Seabra AB. Virus Res. 2021;291:198202.
    1. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Akaberi D, Krambrich J, Ling J, et al. Redox Biol. 2020;37:101734.
    1. Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD. Csoma B, Bikov A, Nagy L, et al. Respir Res. 2019;20:156.
    1. Challenging development of storable particles for oral delivery of a physiological nitric oxide donor. Zhou Y, Gaucher C, Fries I, et al. Nitric Oxide. 2020;104-5:1–10.
    1. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. Thomas SR, Mohr D, Stocker R. J Biol Chem. 1994;269:14457–14464.
    1. Protocol of a randomized controlled trial testing inhaled nitric oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2) [PREPRINT] Lei C, Su B, Dong H, et al. medRxiv. 2020
    1. Nitric oxide gas inhalation to prevent COVID-2019 in healthcare providers. Gianni S, Fakhr BS, Morais CCA, et al. medRxiv. 2020
    1. Inhaled nitric oxide in mechanically ventilated patients with COVID-19. Ferrari M, Santini A, Protti A, et al. J Crit Care. 2020;60:159–160.
    1. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia. Tavazzi G, Pozzi M, Mongodi S, Dammassa V, Romito G, Mojoli F. Crit Care. 2020;24:508.
    1. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Parikh R, Wilson C, Weinberg J, Gavin D, Murphy J, Reardon CC. Ther Adv Respir Dis. 2020;14:1753466620933510.
    1. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe coronavirus disease 2019 (COVID-19) Safaee Fakhr B, Wiegand SB, Pinciroli R, et al. Obstet Gynecol. 2020;136:1109–1113.
    1. ACE2/Angiotensin 1-7 protective anti-inflammatory and antioxidant role in hyperoxic lung injury: support from studies in Bartter's and Gitelman's syndromes. Calò LA, Rigato M, Bertoldi G. QJM. 2020;113:440–441.
    1. An update on the tissue renin angiotensin system and its role in physiology and pathology. Nehme A, Zouein FA, Zayeri ZD, Zibara K. J Cardiovasc Dev Dis. 2019;6:14.
    1. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. J Clin Invest. 1996;97:1916–1923.
    1. Examining and mitigating acellular hemoglobin vasoactivity. Cabrales P. Antioxid Redox Signal. 2013;18:2329–2341.
    1. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Lippi G, Mattiuzzi C. Hematol Transfus Cell Ther. 2020;42:116–117.
    1. Hemoglobin βCys93 is essential for cardiovascular function and integrated response to hypoxia. Zhang R, Hess DT, Qian Z, et al. Proc Natl Acad Sci U S A. 2015;112:6425–6430.
    1. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Hoffmann M, Kleine-Weber H, Pöhlmann S. Mol Cell. 2020;78:779–784.
    1. Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2 pathways. Fang Y, Gao F, Liu Z. QJM. 2019;112:914–924.
    1. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Intensive Care Med. 2020;46:586–590.
    1. The global phosphorylation landscape of SARS-CoV-2 infection. Bouhaddou M, Memon D, Meyer B, et al. Cell. 2020;182:685–712.
    1. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Hirano T, Murakami M. Immunity. 2020;52:731–733.
    1. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H. Diabetologia. 2011;54:2978–2986.
    1. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. Freund A, Patil CK, Campisi J. EMBO J. 2011;30:1536–1548.
    1. The L-arginine-nitric oxide pathway. Moncada S, Higgs A. N Engl J Med. 1993;329:2002–2012.
    1. Comorbidity and its impact on patients with COVID-19. Sanyaolu A, Okorie C, Marinkovic A, et al. SN Compr Clin Med. 2020;2:1069–1076.
    1. Nox4 regulates the eNOS uncoupling process in aging endothelial cells. Lee HY, Zeeshan HM, Kim HR, Chae HJ. Free Radic Biol Med. 2017;113:26–35.
    1. High-affinity uptake of kynurenine and nitric oxide-mediated inhibition of indoleamine 2,3-dioxygenase in bone marrow-derived myeloid dendritic cells. Hara T, Ogasawara N, Akimoto H, et al. Immunol Lett. 2008;116:95–102.
    1. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Mellor AL, Munn DH. Nat Rev Immunol. 2004;4:762–774.
    1. Arginase inhibition improves endothelial function in patients with familial hypercholesterolaemia irrespective of their cholesterol levels. Kovamees O, Shemyakin A, Eriksson M, Angelin B, Pernow J. J Intern Med. 2016;279:477–484.
    1. Novel therapeutic targets for phosphodiesterase 5 inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis. Vasquez EC, Gava AL, Graceli JB, Balarini CM, Campagnaro BP, Pereira TM, Meyrelles SS. Curr Pharm Biotechnol. 2016;17:347–364.
    1. Nitrite supplementation reverses vascular endothelial dysfunction and large elastic artery stiffness with aging. Sindler AL, Fleenor BS, Calvert JW, Marshall KD, Zigler ML, Lefer DJ, Seals DR. Aging Cell. 2011;10:429–437.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren